Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.
In 1953, Dr. Paul Janssen established Janssen Pharmaceutica, a pharmaceutical research laboratory based in Beerse, Belgium. This company became part of Johnson & Johnson in 1961.
In 1958, Dr. Janssen created haloperidol, the first representative of a completely new chemical family of antipsychotics. It quickly became the drug of choice in the emergency management of psychiatric agitation and revolutionized the treatment of schizophrenia. Dr. Paul Janssen and his team did not stop their work after the success of Haloperidol, they increased their efforts furthermore not only in new molecules discovery; Risperidone and Paliperdione, but also novel drug delivery systems as in Risperdal Consta the first long acting atypical antipsychotic, INVEGA SUSTENNA the first once monthly atypical antipsychotic, and even more to come.
With a longstanding, continued commitment to neuroscience, our vision is to reduce the burden, disability and devastation caused by serious neuropsychiatric diseases and restore hope for patients.
For more information please visit: www.janssen.com